IN BRIEF: MGC Pharmaceuticals rejigs board to reflect strategic change

Archived article

Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.

MGC Pharmaceuticals Ltd - London-based pharmaceutical company specialising in plant-inspired medicines - Says Brett Mitchell and Nativ Segev, will step down from the board, reflecting the changing direction of the company as it moves away from the medicinal cannabis sector toward a more pharma-focused business strategy. Stephen Parker, currently non-executive director, will replace Mitchell as interim non-executive chair. A new Australian non-executive director will also be appointed. Appoints Oberon Capital as joint broker in the UK with immediate effect alongside Peterhouse Capital.

Current stock price: 0.38 pence, up 0.5% in London on Tuesday

12-month change: down 65%

Copyright 2023 Alliance News Ltd. All Rights Reserved.